Stephen Machatha sold $114k of ALDX
Chief Development Officer at Aldeyra Therapeutics, Inc.. 22,073 shares at an average of $5.15, traded Aug 11, 2025, filed Aug 13, 2025.
Score components
- +15RoleOfficer
- +10Trade size$114k at market
- 0Share of holdings soldSold 9.1% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-108210, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 11, 2025 | SOpen-market sale Common Stock | -22,073 | $5.15 | $114k | 221,799 | Aug 13, 2025 |
Related signals
Other insiders at Aldeyra Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 27Weak | ALDXbuy Aldeyra Therapeutics, Inc. | Michael Alfieri Principal Financial Officer | $13k 2,500 shares | - | |
| 47Moderate | ALDXsell Aldeyra Therapeutics, Inc. | Perceptive Advisors LLC owner | $4.8M 3,400,000 shares | -37% | |
| 23Weak | ALDXbuy Aldeyra Therapeutics, Inc. | Nancy Miller-Rich director | $10k 922 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.